Braunstein Scott 4

What Happened

• Scott Braunstein, a director of Caribou Biosciences (CRBU), was granted a derivative award on Feb 20, 2026 to acquire 45,000 shares. The Form 4 reports the acquisition (code A) at $0.00 (derivative award); no cash purchase or immediate sale was reported.
• This is an equity award/option-style grant as part of compensation, not an open-market purchase or sale. The filing does not indicate an immediate exercise or sale of shares.

Key Details

• Transaction date: 2026-02-20; transaction type: Award/Acquisition (derivative) reported at $0.00.
• Shares involved: 45,000-share award. Total shares owned after the transaction are not specified in the provided summary.
• Vesting: Footnote — one-twelfth of the option vests on each monthly anniversary of the grant date, fully vested on Feb 20, 2027, subject to continued service (see F1).
• Timeliness: Reported on the same date (Period of Report = 2026-02-20), indicating a timely Form 4 filing.

Context

• This is a grant of a derivative equity award (commonly a stock option or similar). Such awards are typical compensation for directors and do not by themselves imply buying or selling pressure.
• For retail investors: purchases or open-market insider buys are often more directly informative about sentiment; grants like this primarily reflect compensation and vesting conditions. If you track insider ownership changes, watch for later filings that show exercises, sales, or updated balances.